The oral numbers
What the human pharmacokinetics actually show.
LiteratureAstaxanthin is intensely lipophilic. Swallowed, it must dissolve into mixed micelles with dietary fat before the gut can take it up — so absorption tracks the meal, not the dose. In the reference human study (healthy volunteers, single 40 mg dose), lipid-based formulations raised exposure up to ~3.7-fold over a commercial supplement, and the elimination half-life measured 15.9 ± 5.3 hours.1 A 2024 comparative study showed a micellar formulation again outperforming the standard form — twenty years on, the field is still engineering around the same wall.
Route comparison
What the route changes.
| Property | Oral astaxanthin | Injectable (OvoEster™) |
|---|---|---|
| Absorption | Low and variable; micelle-dependent, needs dietary fat | Route-complete — administered dose = delivered dose |
| Meal dependence | Strong — fasting or low-fat meals collapse uptake | None |
| Dose control | Subject- and meal-dependent plasma exposure | Exact and reproducible |
| Pre-use degradation | Softgel oils oxidise on the shelf | Lyophilized under argon; reconstituted at the moment of use |
| Published human record | Extensive — PK, skin, eye, exercise trials | Empty — parenteral use has historically not been permitted in clinical research |
LiteratureThat last row is stated exactly as the record stands: what exists for parenteral astaxanthin is animal intravenous pharmacokinetics — dose-dependent kinetics with saturable hepatic metabolism in rats — and formulation research toward parenteral-grade carriers, nanoemulsions and stealth lipid nanoparticles among them. No human injectable astaxanthin has been brought through the public literature.
The Panacea position
An empty record is an open door.
Panacea technologyThe delivery problem public science has not solved is the one OvoEster™ exists for. Panacea Bio Chem is always enhancing the best formulations: OvoEster™ — esterified astaxanthin, argon-processed, lyophilized cold, supplied in the Lyoprester® dual-chamber cartridge — was synthesized and characterised in-house, tested in vitro and in vivo, and is undergoing clinical trials as we speak, although many further details remain secret.
How the presentation keeps oxygen away from a 13-double-bond chromophore — vacuum, argon, cold lyophilization, sealed actuation — is set out in the formulation chain on the main page; the ester chemistry itself is on the esterified astaxanthin page.
Continue
Return to the main astaxanthin resource — sources for every number on this page are in the reference list (r1, r2, r7, r8, r9). Nothing here is medical advice.
